Chinese healthcare faces a pressing challenge as a significant number of its population with chronic hepatitis B (CHB) are at a heightened risk of developing hepatocellular carcinoma (HCC). Current national surveillance rates fall short, and existing guidelines do not adequately consider the available resources, leading to suboptimal resource allocation. This context invites a re-evaluation of surveillance strategies, emphasizing a precision-based approach that aligns with the specific risk profiles of patients. There’s a critical need to discern the most economically viable and health-effective stratagems that can be integrated into clinical practice, ensuring both extended lifespans and improved quality of life for those affected.
Methodology and Model Development
Researchers adopted a state-transition model to simulate the long-term progression of CHB in Chinese patients, considering various phases of HCC risk. This model classified individuals into distinctive risk groups—low, intermediate, and high—based on specific HCC risk scores. Five surveillance strategies were explored, including biannual monitoring, evaluating their cost-effectiveness in comparison to no surveillance. Essential measurables included life expectancy, quality-adjusted life years (QALYs), total costs, and the incremental cost-effectiveness ratio (ICER), aligned with China’s willingness-to-pay (WTP) threshold.
Key Findings and Interpretations
Among intermediate-risk patients, and when considering the entire cohort, both biannual and annual surveillance were deemed cost-effective (ICER
– Enhanced frequency of surveillance in higher-risk groups improves health outcomes significantly.
– Patients with intermediate risk benefit most from biannual and annual monitoring strategies.
– No surveillance strategy offers economic viability for low-risk patients, indicating potential resource savings.
– Adjustments to mortality rates in advanced disease stages significantly affect outcome predictions.
A risk-stratified framework for HCC surveillance among CHB patients emerges as a pivotal approach, with implications for both financial and health-related outcomes. Tailoring surveillance strategies to specific patient risk levels offers promise for more efficient management of healthcare resources. Biannual surveillance should be prioritized for high-risk patients, while its application for low-risk groups might be judiciously reconsidered. Such precision in designing surveillance could significantly reduce the incidence of HCC and the economic burden on the healthcare system by narrowing the focus to those most at risk. Adapting these tailored strategies into clinical practice could potentially extend and enhance life for many patients struggling with CHB in China, steering the use of limited resources effectively towards patients in dire need.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
